Laser treatment for diabetic macular edema in the 21st century
- PMID: 24852439
- PMCID: PMC4051253
- DOI: 10.2174/1573399810666140402123026
Laser treatment for diabetic macular edema in the 21st century
Abstract
Diabetic macular edema (DME) is the leading cause of blindness in the diabetic population. The diabetes Control and Complications Trial reported that 27% of patients affected by type 1 diabetes develop DME within 9 years of onset. Other studies have shown that in patients with type 2 diabetes, the prevalence increased from 3% to 28% within 5 years of diagnosis to twenty years after the onset. At the present time, despite the enthusiasm for evaluating several new treatments for DME, including the intravitreal therapies for DME (e.g., corticosteroids, and anti-VEGF drugs), laser photocoagulation remains the current gold standard and the only treatment with proven efficacy in a wide range of clinical trials for this condition. Despite being the standard technique for comparison and evaluation of the emerging treatments, we have generally poor understanding of the ETDRS recommendations, and we often forget about the results of laser in DME. The purpose of this review is to update our knowledge on laser photocoagulation for DME with an extensive review of the ETDRS results and discuss the laser techniques. Furthermore, we will describe the new developments in laser systems and review the current indications and results. Finally, we will discuss the results of laser treatments versus the current pharmacological therapies. We conclude by trying to provide a general overview that which laser treatment must be indicated and what types of lasers are currently recommended.
Figures




Similar articles
-
Intravitreal aflibercept for diabetic macular edema.Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8. Ophthalmology. 2014. PMID: 25012934 Clinical Trial.
-
The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema.Curr Opin Ophthalmol. 2017 May;28(3):205-212. doi: 10.1097/ICU.0000000000000362. Curr Opin Ophthalmol. 2017. PMID: 28151747 Review.
-
Diabetic macular edema: changing treatment paradigms.Curr Opin Ophthalmol. 2014 Nov;25(6):502-7. doi: 10.1097/ICU.0000000000000102. Curr Opin Ophthalmol. 2014. PMID: 25211039 Review.
-
Combined therapy for diabetic macular edema.Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):315-20. doi: 10.4103/0974-9233.120014. Middle East Afr J Ophthalmol. 2013. PMID: 24339681 Free PMC article. Review.
-
[Evaluate the effectiveness of laser therapy in the treatment of diabetic maculopathy].Pol Merkur Lekarski. 2013 Jun;34(204):351-4. Pol Merkur Lekarski. 2013. PMID: 23882935 Polish.
Cited by
-
Saudi Arabia Guidelines for diabetic macular edema: A consensus of the Saudi Retina Group.Saudi Med J. 2021 Feb;42(2):131-145. doi: 10.15537/smj.2021.2.25623. Saudi Med J. 2021. PMID: 33563731 Free PMC article.
-
Autonomous screening for laser photocoagulation in fundus images using deep learning.Br J Ophthalmol. 2024 May 21;108(5):742-746. doi: 10.1136/bjo-2023-323376. Br J Ophthalmol. 2024. PMID: 37217293 Free PMC article.
-
Adjunct Nondamaging Focal Laser Reduces Intravitreal Injection Burden in Diabetic Macular Edema.Photonics. 2023 Oct;10(10):1165. doi: 10.3390/photonics10101165. Epub 2023 Oct 18. Photonics. 2023. PMID: 39006749 Free PMC article.
-
The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.Acta Ophthalmol. 2018 May;96(3):e377-e385. doi: 10.1111/aos.13574. Epub 2017 Nov 1. Acta Ophthalmol. 2018. PMID: 29090846 Free PMC article. Clinical Trial.
-
Outcomes of Anti-VEGF Therapy in Eyes with Diabetic Macular Edema, Vein Occlusion-Related Macular Edema, and Neovascular Age-Related Macular Degeneration: A Systematic Review.Clin Ophthalmol. 2024 Dec 17;18:3837-3851. doi: 10.2147/OPTH.S489114. eCollection 2024. Clin Ophthalmol. 2024. PMID: 39717563 Free PMC article. Review.
References
-
- Klein R, Klein B E K, Moss S E, Cruickshanks K J. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII.The 14-year incidence and progression of diabetic retinopathy and associated risk factors in Type 1 diabetes . Ophthalmology. 1998;105:1801–1815. - PubMed
-
- Williams Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema. A systematic review Eye. 2004;18:963–983. - PubMed
-
- Romero-Aroca P, Fernández-Balart J, Baget-Bernaldiz M, Martinez-Salcedo I, Méndez-Marín I, Salvat-Serra M, Buil-Calvo JA. Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. J Diabetes Complications. 2009;23:229–238. - PubMed
-
- Diabetes Control and Complications Trial Research Group.Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–661. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical